Heart Disease Trial, Recruiting NCT07023679 Sponsor: The Second Hospital of Anhui Medical University Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT07023679
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any sex
  • People who have had a type of heart attack called a STEMI (where specific changes are seen on a heart tracing test called an ECG), and who are planned to have a procedure to open a blocked heart artery
  • People whose heart attack chest pain started within the last 24 hours
  • People (and their family) who have agreed to take part by signing a consent form

Who may not be able to join:

  • People experiencing severe complications from their heart attack, such as severe heart failure with fluid in the lungs, severe shock after needing resuscitation, or serious structural problems with the heart (such as a hole in the heart wall or torn heart muscle)
  • People who have had a previous heart attack, have a disease affecting the heart muscle, or have dangerous heart rhythm problems that are being managed with medication
  • People who have a condition that affects blood clotting, or who are currently taking blood-thinning medications in a way that would make injections unsafe
  • People who are allergic to opioid pain medications, or who have a history of opioid addiction
  • People who are already taking part in another clinical trial
  • People who are pregnant or breastfeeding
  • People with serious organ problems, such as liver failure, kidney failure, or breathing failure
  • People with a serious active infection
  • People with severe mental health conditions that would make it difficult to participate, or who are taking antipsychotic medications
  • People the research team considers unsuitable for the trial for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 055163869480

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Second Hospital of Anhui Medical University
Registry
ClinicalTrials.gov
Start date
24 June 2025
Est. completion
20 June 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of major adverse cardiovascular and cerebrovascular events (MACCE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov